Archean Chemical's Q1 FY27 saw standalone revenue at 332.1 Cr (up 14% YoY), EBITDA at 83.87 Cr (margin 25.3%), and PAT at 40.53 Cr (up 36% QoQ). Bromine volumes hit a 5-quarter high with realizations up 50% YoY.

Derivatives turned EBITDA positive (1.9 Cr). Sulphate of Potash Phase 1 trials are complete.

Logistics challenges (road construction, higher sea freight/diesel) impacted industrial salt volumes; normalization expected from Q3. Brine lease extension talks are positive.

SiCSem (semicon) execution has begun, targeting production in 24-27 months.

Management expressed confidence in scaling core business and new ventures.